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The total synthesis of calcium atorvastatin†
Luiz C. Dias,*a Adriano S. Vieiraa and Eliezer J. Barreirob
A practical and convergent asymmetric route to calcium atorvastatin (1) is reported. The synthesis of
calcium atorvastatin (1) was performed using the remote 1,5-anti asymmetric induction in the boron-
mediated aldol reaction of β-alkoxy methylketone (4) with pyrrolic aldehyde (3) as a key step. Calcium
atorvastatin was obtained from aldehyde (3) after 6 steps, with a 41% overall yield.
Introduction
Calcium atorvastatin (1), the active ingredient of Liptor®, a
statin launched in 1997, competitively inhibits hydroxymethyl-
glutaryl-CoA (HMG-CoA) reductase, the enzyme that catalyzes
the rate-limiting step in cholesterol biosynthesis (Fig. 1).1 Due
to its high efficacy for LDL cholesterol reduction and its estab-
lished safety profile, an ongoing demand for calcium atorvas-
tatin is expected, and the development of an efficient, robust
and scalable synthetic route to (1) is of remarkable interest for
academia and the pharmaceutical industry.2,3
Many different routes to statin side chains have been
reported using chemical and biocatalytic steps to introduce
one of the two stereogenic centers.4–9 Recently, Shibasaki and
coworkers developed a direct catalytic asymmetric aldol reac-
tion promoted by a soft Lewis acid catalyst using thioamides
as the aldol donors, and they applied this methodology to the
enantioselective synthesis of atorvastatin.10
In this study, we describe our approach to atorvastatin
based on a 1,5-anti asymmetric aldol reaction of β-alkoxy
methyl ketone 4 with aldehyde 3.11,12
Results and discussion
A process chemistry development program was undertaken to
improve the synthesis of calcium atorvastatin (1) using the
remote 1,5-asymmetric induction in a boron-mediated aldol
reaction of pyrrolic aldehyde (3)13–16 with β-alkoxy methyl-
ketone (4)17–19 as a key step (Scheme 1).
The key building blocks aldehyde 3 and methylketone 4 are
known compounds and are synthesized by the described pro-
cedures, with slight modifications (see the ESI†).13–19 We
began our approach with the boron-mediated aldol reaction.
For this purpose, methylketone (4) was treated with dicyclo-
hexyl chloroborane (c-Hex2BCl) in Et2O, at 0 °C, followed by
the addition of excess triethylamine to generate the corres-
ponding kinetic boron enolate over 1 h (Scheme 2). The reac-
tion was cooled to −78 °C, the solution of the pyrrole aldehyde
Fig. 1 Calcium atorvastatin (1).
Scheme 1 Retrosynthetic analysis of calcium atorvastatin (1).
†Electronic supplementary information (ESI) available: 1H NMR, 13C NMR, IR,
and HRMS spectra of the prepared compounds. See DOI: 10.1039/c5ob02546j
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(3) in Et2O was added slowly, and the reaction was maintained
for 3 h at this temperature.11,12
The respective aldol product 5 was obtained in 81% yield
with a selectivity of 91 : 9 in favor of the desired 1,5-anti dia-
stereoisomer, according to the NMR analysis of the crude
mixture (Scheme 2). The aldol reaction was performed on a
scale of 50 g of the pyrrole aldehyde (3) without affecting the
yield and stereoselectivity of the reaction. The product in the
form of the diastereoisomeric mixture was used in the next
step without purification. An analytical sample was chromato-
graphed on silica gel to achieve the physical characterization
of the β-hydroxyketone product 5.
The diastereoselective syn-reduction reaction of β-hydroxy-
ketone 5 was achieved using NaBH4 as the reducing agent in
the presence of diethyl methoxy borane as a chelating agent
(Scheme 2).20 The syn-1,3-diol acetonide product 6 was
obtained in 87% yield with a high diastereomeric ratio >95 : 5
in favor of the desired 1,3-syn-isomer. The crude product was
used in the next step without purification. An analytical
sample was chromatographed on silica gel to achieve the
physical characterization of 6. In the next step, the diol aceto-
nide was subjected to simple acid hydrolysis (HCl 1 N, H2O/
THF), providing tetra-ol (2), as depicted in Scheme 3. At this
stage, we were able to purify the tetra-ol (2) to obtain the single
isomer. Crude tetra-ol (2) (17.2 g) was dissolved in isopropyl
alcohol (20 mL) under stirring at 25 °C. Then, hexane (100 mL)
was slowly added over 1 h, and the mixture was allowed to
stand in a refrigerator at 4 °C overnight to afford tetra-ol as a
white crystalline solid and as a single isomer in 90% yield, as
observed by NMR analysis (dr > 99 : 1).
Following the reaction sequence, tetra-ol (2) was subjected
to an oxidative cleavage reaction with sodium periodate in
alkaline medium,21 providing atorvastatin lactol (7) in 88%
yield as a white crystalline solid (Scheme 3). Atorvastatin lactol
(7) has been described in the literature, although it was
obtained through a different process.22 A small analytical
sample of 7 was purified by flash column chromatography on
silica gel to achieve its physical characterization, which was
performed using NMR spectroscopy and HRMS analysis. The
physical data were appropriately compared with the literature
data.22
Atorvastatin lactol (7) was subjected to selective oxidation
in the presence of excess activated MnO2 to provide atorvasta-
tin lactone (8), which was obtained in 95% isolated yield after
recrystallization (Scheme 3).22 Atorvastatin lactone (8) is a key
intermediate in the original synthesis of calcium atorvastatin
(1). The physical data for atorvastatin lactone (8) ([α]20D = +25°, c
= 1, CHCl3, lit: [α]
20
D +26°, c = 1, CHCl3) are in full agreement
with the literature.1c,4b,22
In the last step, the treatment of lactone (8) with 10%
sodium hydroxide in MeOH and MBTE followed by treatment
of the resulting salt with calcium acetate monohydrate in
water, at rt, provided calcium atorvastatin (1) in 94% isolated
yield (Scheme 4). To confirm that the active amorphous
calcium atorvastatin (1) was obtained, we performed powder
Scheme 2 Aldol reaction and diastereoselective reduction of β-hydro-
xyketone 5.
Scheme 3 Acid hydrolysis reaction of acetonide 6 and preparation of
lactone 8.
Scheme 4 Synthesis of calcium atorvastatin (1).
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X-ray diffraction and solid-state NMR analysis. The physical
data (nuclear magnetic resonance, powder X-ray diffraction23
and optical rotation4b) are in full agreement with the values
reported in the literature.
Conclusions
In summary, we developed a scalable, practical asymmetric
synthesis of calcium atorvastatin (1). The scalable process
employs a highly efficient 1,5-asymmetric induction in a
boron-mediated aldol reaction as a key step. In the process
development, 3 new atorvastatin intermediates (compounds 2,
5 and 6) were produced. Calcium atorvastatin (1) was obtained
after 6 steps with 41% overall yield.
Experimental
Materials and methods
Unless noted, all reactions were performed under an atmos-
phere of argon with dry solvents and magnetic stirring. Tri-
ethylamine (Et3N) was distilled from CaH2. Tetrahydrofuran
(THF) and diethyl ether (Et2O) were distilled from sodium/ben-
zophenone. Methanol (MeOH) was distilled from Mg(OMe)2
and stored over molecular sieves. Yields refer to homogeneous
materials obtained after purification of reaction products by
flash column chromatography using silica gel (200–400 mesh).
Analytical thin-layer chromatography was performed on silica-
gel 60 and GF (5–40 μm thickness) plates, and visualization
was accomplished using UV light and phosphomolybdic acid
staining followed by heating. Optical rotations were measured
with a sodium lamp and are reported as follows: [α]TD
(°C)
(c (g per 100 mL), solvent). Melting points are uncorrected. For
infrared spectra (IR), wavelengths of maximum absorbance
(νmax) are quoted in wavenumbers (cm
−1). 1H and proton-
decoupled 13C NMR spectra were acquired in C6D6, CDCl3,
DMSO-d6 or CD3OD at 250 MHz (
1H) and 62.5 MHz (13C), at
400 MHz (1H) and 100 MHz (13C), at 500 MHz (1H) and
125 MHz (13C), or at 600 MHz (1H) and 150 MHz (13C). Chemi-
cal shifts (δ) are reported in ppm using residual undeuterated
solvent as an internal standard (C6D6 at 7.16 ppm, CDCl3 at
7.25 ppm, CD3OD at 3.30 ppm, and TMS at 0.00 ppm for
1H NMR spectra and C6D6 at 128.0 ppm, CDCl3 at 77.0 ppm,
CD3OD at 49.0 ppm for
13C NMR spectra). Multiplicity data are
reported as follows: s = singlet, d = doublet, t = triplet, q =
quartet, br s = broad singlet, dd = doublet of doublets, dt =
doublet of triplets, ddd = doublet of doublet of doublets, ddt =
doublet of doublet of triplets, dtd = doublet of triplet of doub-
lets, dqd = doublet of quartet of doublets, m = multiplet, and
br m = broad multiplet. The multiplicity is followed by the
coupling constant(s) in Hz and integration. High-resolution
mass spectra (HRMS) were measured by electrospray ionization
(ESI). Samples were analyzed using a hybrid 7 T Fourier trans-
form ion cyclotron nanoelectrospray ionization source. The
nanoelectrospray conditions were a flow rate of 200 nL min−1,
back pressure of approximately 0.4 psi, and electrospray vol-
tages of 1.5–2.0 kV over 60 s and were controlled by ChipSoft
software. Mass resolution was fixed at 100 000 at m/z 400. Data
were obtained as transient files (scans recorded in the time
domain). All samples were evaluated in positive ESI(+) ion
mode, and spectra were acquired in the m/z 150–1500 range.
Samples were analyzed directly in a 10 μg mL−1 methanol solu-
tion without any sample treatment or dilution.
Synthesis
1-(R)-6-(S)-2,2-(Dimethyl-1,3-dioxolan-4-yl)-3-(hydroxy-5-oxo-
hexyl)-5-(4-fluorophenyl)-2-isopropyl-N,4-diphenyl-1H-pyrrole-
3-carboxamide (5). To a solution of methylketone (4) (35.0 g,
220 mmol) in anhydrous Et2O (700 mL) under an argon atmos-
phere at 0 °C was added c-Hex2BCl (95.0 mL, 440 mmol) over
50 min. Next, triethylamine (108.0 mL, 770 mmol) was slowly
added over 40 min. The reaction mixture was stirred for 1 h at
0 °C to generate the kinetic boron enolate. Then, the reaction
was cooled to −78 °C, and pyrrole aldehyde (3) (50.0 g,
110 mmol) dissolved in Et2O (300 mL) was slowly added to the
solution of the generated boron enolate over 1 h. The reaction
was stirred for 3 h at −78 °C, quenched by the addition of
methanol (100 mL) and warmed to 25 °C. The solvent was
removed under reduced pressure (30 °C/150 mmHg), and the
residue was purified by passing through a plug of silica
(hexanes/acetate 7 : 3). The unreacted ketone (4) (15.7 g) was
recovered. The product 5 (dr 91 : 9 according to 1H NMR ana-
lysis) was obtained as a white solid (81% yield; 54.6 g). Mp
62–64 °C. [α]20D = + 2.3° (c = 1.0, CHCl3).
1H NMR (250 MHz,
C6D6) δ 1.33 (s, 3H), 1.43 (s, 3H), 1.50–1.78 (m, 3H), 1.86 (d, J =
7.0 Hz, 6H), 1.92–2.01 (m, 2H), 2.32 (dd, J = 15.0 Hz, 6.7 Hz,
1H), 2.94 (s, 1H), 3.34 (t, J = 7.5 Hz, 1H), 3.73–3.79 (m, 2H),
3.94–4.00 (m, 2H), 4.13–4.31 (m, 2H), 6.77–7.01 (m, 7H),
7.10–7.16 (m, 4H), 7.30 (d, J = 8.0 Hz, 2H), 7.45 (d, J = 8.0 Hz,
2H). 13C NMR (125 MHz, C6D6) δ 21.9, 22.1, 25.5, 26.7, 27.0,
38.2, 41.4, 47.2, 49.4, 64.8, 69.3, 71.7, 109.0, 115.6 (d, JC–F =
21.3 Hz), 116.9, 119.4, 122.4, 123.5, 126.7, 127.8, 127.9, 128.5,
128.8 (d, JC–F = 5.0 Hz), 129.0, 133.5 (d, JC–F = 8.8 Hz), 135.2,
139.5, 141.8, 162.5 (d, JC–F = 247.6 Hz), 164.7, 208.2. IR (thin
film, cm−1): 3405, 2975, 1729, 1671. HRMS (ESI-TOF) m/z calcd
for C37H42FN2O5 (M + H)
+ 613.3077, found 613.3078.
1-(3R,5R)-6-[(S)-2,2-(Dimethyl-1,3-dioxolan-4-yl)]-3,5-dihydroxy-
hexyl-5-(4-fluorophenyl)-2-isopropyl-N,4-diphenyl-1H-pyrrole-3-
carboxamide (6). To a solution of (5) (50.0 g, 81.7 mmol) in
THF/MeOH (4 : 1) (600 mL) under an argon atmosphere at
−78 °C was slowly added Et2B(OMe) (15.0 mL, 89.8 mmol) over
30 min. After 40 min, NaBH4 (3.4 g, 89.8 mmol) was added in
portions, and the reaction mixture was maintained at −78 °C
for 3 h. The reaction was quenched by the addition of glacial
acetic acid (70 mL), methanol (70 mL) and 30% H2O2 (20 mL).
The mixture was vigorously stirred for 30 min and was
extracted with ethyl acetate (3 × 400 mL). Next, the organic
phase was washed with brine (2 × 200 mL), and the solvent
was removed under reduced pressure. The product (6) can be
used in the next step without purification. An analytical
sample was purified by silica gel flash column chromatography
Organic & Biomolecular Chemistry Paper
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(hexane/acetate 8 : 2) to achieve the physical characterization of
1,3-diol (6). The product (6) was obtained as a white solid in
87% yield (43.6 g, 71.0 mmol). Mp 71–73 °C. [α]20D = +2.5 (c =
1.0, CHCl3).
1H NMR (500 MHz, C6D6) δ 1.26–1.33 (m, 10H),
1.60–1.73 (m, 2H), 1.77 (d, J = 7.2 Hz, 6H), 3.29–3.32 (m, 1H),
3.40 (s, 1H), 3.61 (s, 1H), 3.74–3.77 (m, 3H), 3.90–4.08 (m, 3H),
4.15–4.23 (m, 1H), 6.71 (t, J = 8.5 Hz, 2H), 6.80 (s, 1H),
6.82–6.95 (m, 4H), 7.03–7.16 (m, 4H), 7.23 (d, J = 8.5 Hz, 2H),
7.36 (d, J = 8.5 Hz, 2H). 13C NMR (125 MHz, C6D6) δ 22.0, 22.2,
25.6, 26.7, 26.9, 39.9, 40.6, 41.5, 43.0, 69.3, 69.9, 70.2, 73.3,
109.0, 115.4 (d, JC–F = 21.3 Hz), 116.7, 119.5, 122.4, 123.6,
126.7, 127.9, 128.2, 128.4 (d, JC–F = 5.0 Hz), 129.0, 130.7, 133.5
(d, JC–F = 7.5 Hz), 135.8, 139.4, 141.7, 162.5 (d, JC–F = 247.6 Hz),
165.0. HRMS (ESI-TOF) m/z calcd for C37H44FN2O5 (M + H)
+
615.3234, found 615.3235. IR (thin film, cm−1): 3415, 2973,
1669.
5-(4-Fluorophenyl)-2-isopropyl-N,4-diphenyl-1-((3R,5R,7S)-
3,5,7,8-tetrahydroxyoctyl)-1H-pyrrole-3-carboxamide (2). To
a solution of 1-((3R,5R)-6-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)-
3,5-dihydroxyhexyl)-5-(4-fluorophenyl)-2-isopropyl-N,4-diphenyl-
1H-pyrrole-3-carboxamide (6) (40.0 g, 65.1 mmol) in THF
(600 mL) at 25 °C was slowly added aqueous 1 M HCl
(64.0 mL) over 15 min. The reaction mixture was kept under
stirring for 4 h, and over this time, a saturated aqueous
NaHCO3 solution (200 mL) was added (until pH = 8). The
mixture was extracted with ethyl acetate (3 × 400 mL), the
solvent was removed under vacuum, and the residue was
recrystallized from isopropyl alcohol/hexane. Tetra-ol (2) was
obtained as a white solid in 90% yield (33.6 g, 58.6 mmol) as a
single isomer according to 1H NMR analysis. Mp 85–88 °C.
[α]20D = +3.2 (c = 1.0, MeOH).
1H NMR (500 MHz, CD3OD)
δ 1.37–1.41 (m, 2H), 1.48–1.54 (m, 7H), 1.59–1.80 (m, 3H),
3.30–3.40 (m, 3H), 3.65 (s, 1H), 3.78–3.92 (m, 4H), 7.01–7.31
(m, 14H). 13C NMR (125 MHz, MeOD) δ 22.8, 27.6, 40.4, 41.8,
42.3, 45.3, 67.8, 68.0, 69.0, 70.0, 116.3 (d, JC–F = 22.6 Hz),
118.0, 121.5, 123.3, 125.2, 126.9, 128.9, 129.6, 130.2 (d, JC–F =
3.8 Hz), 130.3, 130.9, 134.7 (d, JC–F = 8.8 Hz), 136.3, 139.1,
139.8, 163.8 (d, JC–F = 246.3 Hz), 169.5. HRMS (ESI-TOF) m/z
calcd for C34H40FN2O5 (M + H)
+ 575.2922, found 575.2921.
IR (thin film, cm−1): 3413, 2972, 1668.
1-[2-((2R,4R)-4,6-Dihydroxytetrahydro-2H-pyran-2-yl)ethyl]-
5-(4-fluorophenyl)-2-isopropyl-N,4-diphenyl-1H-pyrrole-3-carb-
oxamide (7). To a solution of tetra-ol (2) (32.0 g, 54.8 mmol) in
anhydrous ethanol (500 mL) at 0 °C was slowly added a solu-
tion of NaIO4 (35.2 g, 164.4 mmol) and NaOH (0.216 g,
5.4 mmol) in 90 mL of H2O. The reaction mixture was stirred
for 2 h at 25 °C, and a saturated aqueous solution of NH4Cl
(300 mL) was added. The mixture was extracted with ethyl
acetate (3 × 400 mL) and washed with brine (200 mL). Lactol
(7) was obtained as a white solid in 88% yield (25.6 g,
47.4 mmol). Mp 103–107 °C. 1H NMR (500 MHz, CDCl3)
δ 1.37–1.50 (m, 1H), 1.53 (d, J = 7.0 Hz, 6H), 1.65–1.83 (m, 3H),
1.86–1.89 (m, 2H), 3.51–3.54 (m, 1H), 3.82–3.94 (m, 1H),
4.08–4.13 (m, 4H), 4.27 (d, J = 7.5 Hz, 1H), 5.18 (s, 1H),
6.90 (s, 1H), 6.96–7.20 (m, 14H). 13C NMR (125 MHz, CDCl3)
δ 21.7, 21.8, 26.1, 35.0, 37.4, 39.5, 41.4, 60.4, 65.0, 92.5,
115.3 (d, JC–F = 21.3 Hz), 119.6, 120.1, 121.8, 123.6, 126.5,
128.1 (d, JC–F = 2.5 Hz), 128.5, 128.8, 129.7, 130.4, 133.1 (d,
JC–F = 8.8 Hz), 134.5, 138.1, 141.2, 162.2 (d, JC–F = 247.6 Hz),
165.0. HRMS (ESI-TOF) m/z calcd for C33H36FN2O4 (M + H)
+
543.2659, found 543.2659. IR (thin film, cm−1): 3414, 2973,
1670.
5-(4-Fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxotetrahydro-
2H-pyran-2-yl)ethyl]-2-isopropyl-N,4-diphenyl-1H-pyrrole-3-carb-
oxamide (8) (atorvastatin lactone). To a solution of atorvastatin
lactol (7) (24.0 g, 44.2 mmol) in acetone (350 mL) was added
activated MnO2 (37.4 g, 442.0 mmol) at 25 °C. The suspension
was kept under stirring for 24 h at 25 °C. The reaction mixture
was filtered, and the solvent evaporated. Atorvastatin lactone
(8) was obtained in 95% (22.7 g, 42.0 mmol) yield as a white
crystalline solid. Mp 159–161 °C. [α]20D = +26.9° (c = 1.0, CHCl3)
(obtained). Lit:4b [α]20D = +26.0° (c = 1.0, CHCl3).
1H NMR
(250 MHz, CDCl3) δ 1.52 (d, J = 7.0 Hz, 6H), 1.58–1.90 (m, 4H),
2.54–2.58 (m, 2H), 2.89 (s, 1H), 3.49–3.55 (m, 1H), 4.01–4.24
(m, 3H), 4.48–4.52 (m, 1H), 6.91 (s, 1H), 6.99–7.21 (m, 14H).
13C NMR (62.5 MHz, CDCl3) δ 21.6, 21.9, 26.1, 35.5, 37.0, 38.4,
40.6, 62.1, 73.0, 115.5 (d, JC–F = 21.3 Hz), 115.7, 119.7, 122.0,
123.7, 126.6, 127.9, 128.3, 128.6 (d, JC–F = 5.6 Hz), 128.8, 130.3,
133.0 (d, JC–F = 8.2 Hz), 134.3, 138.0, 141.2, 162.3 (d, JC–F =
247.8 Hz), 165.0, 169.7. IR (thin film, cm−1): 3410, 2952, 1750,
1673.
Calcium atorvastatin (1). To a solution of atorvastatin
lactone (8) (20.0 g, 37.0 mmol) in methanol (50 mL) and
methyl-tert-butyl ether (MTBE) (130 mL) was added NaOH
(1.53 g, 38.1 mmol) dissolved in water (250 mL). The resulting
mixture was stirred for 2 h at 50 °C. After cooling (20 °C), the
phases were separated, and the aqueous phase (which con-
tains the product) was washed with MTBE (80 mL). The
aqueous phase was separated and the pH was adjusted to 8.0
by the addition of aqueous 1 M HCl; the solution was then
heated at 50 °C. The resulting mixture was treated with a solu-
tion of calcium acetate monohydrate (3.27 g, 20.3 mmol) in
water (70 mL), and the mixture was heated to 50 °C. The reac-
tion was stirred for 30 min, and it was slowly cooled to 30 °C
for 4 h. The precipitated product (1) was filtered and washed
with methanol/H2O (1 : 1) (150 mL). Calcium atorvastatin (1)
was obtained as a white amorphous solid in 94% yield (20.1 g,
17.4 mmol) after recrystallization in THF/MeOH/H2O and
drying under high vacuum for 12 h. Purity by HPLC: 99.98%,
(>99.5 ee). Mp 174–178 °C. Lit.22a mp 177–182 °C. [α]20D = −7.1°
(c = 1.0, DMSO). Lit4b [α]20D = −7.4° (c = 1.0, DMSO). 1H NMR
(500 MHz, DMSO-d6) δ 1.22–1.25 (m, 1H), 1.37 (d, J = 7.0 Hz,
6H), 1.40–1.42 (m, 1H), 1.51–1.62 (m, 2H), 1.94–1.98 (m, 1H),
2.08–2.11 (m, 1H), 3.21–3.24 (m, 1H) 3.36 (s, 2H), 3.54 (s, 1H),
3.70–3.78 (m, 2H), 3.93–3.97 (m, 1H), 6.86–7.01 (m, 2H),
7.06–7.08 (m, 4H), 7.16–7.26 (m, 6H), 7.51 (d, J = 8.0 Hz, 2H),
9.80 (s, 1H). 13C NMR (125 MHz, DMSO-d6) δ 22.2, 22.3, 25.6,
39.9, 40.8, 43.6, 43.9, 66.2 (2C), 115.3 (d, JC–F = 20.1 Hz), 117.4,
119.4, 120.5, 122.9, 125.3, 127.2, 127.6, 128.5, 128.7 (d, JC–F =
2.5 Hz), 129.1, 133.3 (d, JC–F = 8.7 Hz), 134.9, 135.9, 139.4,
161.5 (d, JC–F = 245.1 Hz), 166.1, 178.1. IR (KBr, cm
−1) 3418,
3062, 2961, 2873, 1793, 1660, 1528, 1480.
Paper Organic & Biomolecular Chemistry
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